Advanced Search

Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 57.33 2.05% 1.15
ZNTL closed up 2.05 percent on Wednesday, May 5, 2021, on 83 percent of normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical ZNTL trend table...
Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Multiple of Ten Bearish Other 2.05%
Wide Bands Range Expansion 2.05%
Overbought Stochastic Strength 2.05%
Hammer Candlestick Bullish -4.59%
Doji - Bullish? Reversal -4.59%
Multiple of Ten Bullish Other -4.59%
Wide Bands Range Expansion -4.59%
Older End-of-Day Signals for ZNTL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 9 hours ago
Possible Inside Day about 10 hours ago
60 Minute Opening Range Breakout about 11 hours ago
Up 3% about 11 hours ago
Down 1% about 13 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators Basic chart:

Profile

  • Earnings date: ???
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Hormones Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Her2 Molecule Therapeutics Her2/Neu Transcription Factors Estrogen Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors

Is ZNTL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 28 The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Apr 20 Gain Therapeutics inks multi-target drug discovery collaboration agreement with zentalis
Apr 20 Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
Apr 12 Zentalis surges on clinical collaboration with GlaxoSmithKline
Apr 12 Zentalis's Early WEE1 Inhibitor Data Shows 'Exceptional' Response In Solid Tumor Study, Plans Combination Trials
Apr 12 Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor
Apr 12 51 Biggest Movers From Friday
Apr 10 Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors
Apr 3 The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight
Mar 25 Zentalis Pharmaceuticals EPS misses by $0.06
See more ZNTL news...

Indicators

Indicator Value
52 Week High 62.79
52 Week Low 25.41
Average Volume 317,535
200-Day Moving Average 42.16
50-Day Moving Average 47.09
20-Day Moving Average 53.08
10-Day Moving Average 59.07
Average True Range 3.92
ADX 26.33
+DI 21.34
-DI 15.11
Chandelier Exit (Long, 3 ATRs ) 51.03
Chandelier Exit (Short, 3 ATRs ) 49.03
Upper Bollinger Band 67.44
Lower Bollinger Band 38.71
Percent B (%b) 0.65
BandWidth 54.12
MACD Line 3.97
MACD Signal Line 3.94
MACD Histogram 0.0313
Fundamentals Value
Market Cap 2.33 Billion
Num Shares 40.6 Million
EPS -99999.99
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 6.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 63.45
Resistance 3 (R3) 63.42 61.36 62.43
Resistance 2 (R2) 61.36 59.80 61.37 62.09
Resistance 1 (R1) 59.34 58.84 60.35 59.37 61.75
Pivot Point 57.28 57.28 57.78 57.29 57.28
Support 1 (S1) 55.26 55.72 56.27 55.29 52.91
Support 2 (S2) 53.20 54.76 53.21 52.57
Support 3 (S3) 51.18 53.20 52.23
Support 4 (S4) 51.21